5 min. Read

FDA OKs Alivecor (12L?), Akili OTC. Oui eyes obesity.

Issue 227

Welcome back to E&O: SaMD, a paying subscribers-only weekly newsletter focused on the world of digital pharma products, prescription digital therapeutics and other FDA-regulated digital health.

E&O: Software as a Medical Device

Here are

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Full access to E&O's research and newsletters.

Get the subscribers-only newsletters + research reports + databases

Help me get ahead. $200/year

Newsletters

Mahana Therapeutics’ insolvency. FDA clears Happy Ring (Tinder founder’s smart ring)

10.04.24

6 min. Read

Flashback: How Proteus Digital Health’s outcomes-based pricing worked for Tennessee Medicaid

9.20.24

5 min. Read

Are the Digital Mental Health Treatment G Codes necessary? Or RTM dupes?

7.12.24

7 min. Read

Which PDTs are still around? New bill in Congress.

6.28.24

10 min. Read

Modern Health EAP pricing. Kellogg’s benefits.

6.07.24

8 min. Read

Digging into the Akili-Virtual Therapeutics deal

5.31.24

10 min. Read

CMS questions MedRhythms on InTandem

5.17.24

5 min. Read

Big Health GTM. Gabbi pricing. Oracle employee benefits

5.10.24

7 min. Read

MedRhythms-Alexion. Akili RCT for OTC.

4.26.24

6 min. Read

Hints about Otsuka’s commercialization plan for Rejoyn

4.16.24

6 min. Read

FDA OKs Alivecor (12L?), Akili OTC. Oui eyes obesity.

E&O: Software as a Medical Device

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.